1-2 of 2
Paul A Sprengeler, PhD
Close
Sort by
Journal Articles

Preclinical Evaluation of eFT226, a Novel, Potent and Selective eIF4A Inhibitor with Anti-Tumor Activity in B-Cell Malignancies

Peggy A Thompson, PhD, Boreth Eam, Nathan P Young, PhD, Sarah Fish, Joan Chen, PhD, Maria Barrera, Haleigh Howard, Ana Parra, Jolene Molter, Jocelyn Staunton, Ivy NJ Hung, PhD, Greg S Parker, PhD, Gary G Chiang, PhD, Chris J Wegerski, PhD, Andres Nevarez, Jeff Clarine, Sam Sperry, PhD, Alan Xiang, PhD, Chinh Tran, Christian Nilewski, PhD, Garrick K Packard, PhD, Theodore Michels, PhD, Paul A Sprengeler, PhD, Justin T Ernst, PhD, Siegfried H Reich, PhD, Kevin R Webster, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1530.
https://doi.org/10.1182/blood.V130.Suppl_1.1530.1530
Published: 2017
Journal Articles

eFT508, a Potent and Selective Mitogen-Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 Inhibitor, Is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma (DLBCL)

Kevin R. Webster, PhD, Vikas K Goel, PhD, Ivy NJ Hung, PhD, Gregory S Parker, PhD, Jocelyn Staunton, BA, Melissa Neal, Jolene Molter, Gary G Chiang, PhD, Katti A. Jessen, PhD, Christopher J Wegerski, PhD, Samuel Sperry, PhD, Vera Huang, PhD, Joan Chen, PhD, Peggy A Thompson, PhD, James R Appleman, PhD, Stephen E Webber, PhD, Paul A Sprengeler, PhD, Siegfried H Reich, PhD
Journal: Blood
Blood (2015) 126 (23): 1554.
https://doi.org/10.1182/blood.V126.23.1554.1554
Published: 2015